News and Trends 4 Nov 2016 Roche hits a Speed Bump on the way to a Hemophilia Cure …for the FDA last year. However, four patients have presented with potentially lethal blood clots. In its report, Roche documented two thromboembolic events and two cases of thrombotic microangiopathy. None… November 4, 2016 - 4 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
Best in Biotech 21 Mar 2023 5 advancements in Down syndrome research over the past year …proven to be effective on animal models. The French biotech Aelis Farma developed AF0217, a molecule that counteracts the hyperactivity of CB1 cannabinoid in the brain. With funding from the… March 21, 2023 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 1 Nov 2024 Can AI cure Alzheimer’s disease? …tools help tackle another formidable challenge of modern biotech, Alzheimer’s disease. “Alzheimer’s is an incredibly complex disease with numerous factors at play. You have the buildup of amyloid plaques, tau… November 1, 2024 - 9 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 17 Nov 2017 British Biotech Gets Ready to Launch a New Antibiotic Drug to Fight Resistance …a UK-based biotech, which has met the primary endpoint in a Phase III study. Motif Bio develops new antibiotics, and its candidate, iclaprim, has met its primary efficacy endpoint and… November 17, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 19 Jan 2023 Pathalys Pharma brings in $150M for SHPT trials …biotech companies develop their late-stage therapies and plan to demonstrate that approach through our collaboration with Pathalys.” Earlier this year, Pathalys Pharma announced plans to initiate two phase 3 clinical… January 19, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
More News! 14 Oct 2017 Art and Biology Meet at Nonhuman Networks Exhibition in Berlin …philosophers, including Spačal and Barnett, that will discuss anthropocentrism through non-human points of view. Upcoming events in the Nonhuman Agents series Lecture: Sarah Hermanutz | ill-at-ease seep 28 October 2017,… October 14, 2017 - 5 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 17 Aug 2018 Novo Nordisk Buys British ‘Smart’ Insulin Diabetes Biotech in deal worth €702M Novo Nordisk acquired the UK biotech Ziylo, which develops glucose-responsive insulin treatments for diabetes that act in response to changes in blood sugar levels. The Danish big-pharma, which is already… August 17, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
In Depth 30 Oct 2018 Shuttles, Bubbles and Ultrasound: Crossing the Blood–Brain Barrier …cancer and Alzheimer’s easier. The blood–brain barrier is the gatekeeper to the brain. This highly selective protective sheath regulates the flow of substances in and out and prevents toxins and… October 30, 2018 - 7 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 31 Mar 2025 AstraZeneca bets on Asia: a surge of deals in March amid fraud probe …being tarnished over fraud and alleged smuggling scandals. Table of contents AstraZeneca signs deals with Harbour BioMed and Syneron Bio for platform technologies The drugmaker collaborated with Chinese biotech Harbour… March 31, 2025 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 17 Jan 2025 Are PD-1 and PD-L1 checkpoint inhibitors as good as we thought? …of the St. Giles Laboratory of Human Genetics of Infectious Diseases at Rockefeller University. Moreover, Masoud Tavazoie, co-founder of the immuno-oncology biotech Inspirna, had warned that some biotechs may be… January 17, 2025 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 28 May 2025 Myasthenia gravis treatments: what’s on the horizon? …sclerosis. The biotech is currently recruiting patients for an ongoing phase 1/2 study. NMD Pharma and Immunovant develop myasthenia gravis treatments; how far along are they? Aside from monoclonal antibodies… May 28, 2025 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Interview 26 Oct 2017 Meet John Beadle, the Serial Entrepreneur with the Key to Oncolytic Viruses Serial entrepreneur John Beadle is now at the helm of PsiOxus, an Oxford biotech with some promising virus-based cancer treatments. Oncolytic viruses have been around for a while without much… October 26, 2017 - 8 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email